| Expression pattern: |
DN |
| Associated gene: |
RRAGB, RRAGC, RRAGD, HIF1A, mTORC1 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits CRC cell growth and promotes 5-fluorouracil-induced apoptosis; enhances chemosensitivity to 5-FU. |
| Molecular mechanism: |
Binds RRAGB to interfere with RRAGB-RRAGC/D heterodimer formation, suppressing mTORC1 signaling and lowering HIF1A; antagonizes the HIF1A-RRAGB-mTORC1 positive feedback loop. |
| Biological pathway or process: |
PI3K/AKT/mTOR (inhibits); apoptosis (promotes); proliferation (inhibits); chemoresistance (inhibits); drug resistance (inhibits); other pathway/process (inhibits) |
| Detected method: |
Q
S
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; Mass Spectrometry; RIP (RNA Immunoprecipitation); Co-IP; Transfection; CCK8; EdU Staining; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; In Vivo Animal Model; TUNEL; Western Blot; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis; RNA-seq; Microarray |
| Clinical significance: |
Lower circEXOC6B expression was associated with poor prognosis; circEXOC6B was an independent prognostic factor and associated with improved OS. |
| Description: |
circEXOC6B (hsa_circ_0009043), derived from EXOC6B, is down-regulated in CRC tissues and its low expression correlates with worse outcomes. It suppresses CRC progression and enhances 5-FU sensitivity by binding RRAGB, disrupting RRAGB-RRAGC/D heterodimerization, inhibiting mTORC1 signaling and HIF1A, thereby antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop. |
| Confidence score: |
0.8869 |